Xiaobing Yang

Dr. Xiaobing Yang


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2025 in Biological Procedures Online
Verified
Journal Article
Open access
PDF file
YZYongchun Zou
Yongchun Zou
XWXinliang Wan
Xinliang Wan
QZQichun Zhou
Qichun Zhou
GZGangxing Zhu
Gangxing Zhu
SLShanshan Lin
Shanshan Lin
SWSumei Wang
Sumei Wang
Hepatocellular carcinoma (HCC) is the most prevalent form of primary liver cancer, associated with high morbidity and mortality worldwide. Despite advancements in diagnostic methods and systemic treatments, including tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), the development of drug resistance remains a significant challenge in HCC management. Traditional treatments such as surgical resection and transarterial chemoembolization offer limited efficacy, especially in advanced stages. Although novel therapies like lenvatinib, sorafenib, regorafenib, and ICIs have shown promise, their effectiveness is often hindered by primary and acquired resistance, leading to poor long-term survival outcomes. This review focuses on the molecular mechanisms underlying resistance to targeted therapies and immunotherapies in HCC. Key factors contributing to resistance include alterations in the tumor microenvironment (TME), immune evasion, hypoxia, changes in cellular metabolism, and genetic mutations. Additionally, molecular players such as ferroptosis, autophagy, apoptosis, endoplasmic reticulum stress, ABC transporters, and non-coding RNAs(ncRNAs) are discussed as contributors to drug resistance. Understanding these mechanisms is critical for the development of novel therapeutic strategies aimed at overcoming resistance, improving patient outcomes, and ultimately enhancing survival rates in HCC patients.

1 December 2014 in Complementary Therapies in Medicine
Verified
Journal Article
Open access
XYXiaobing Yang
Xiaobing Yang
WWWanyin Wu
Wanyin Wu
SLShun-Qin Long
Shun-Qin Long
HDHong Deng
Hong Deng
ZPZong-Qi Pan
Zong-Qi Pan
Some patients with non-small-cell lung cancer (NSCLC) respond well to the EGFR tyrosine kinase inhibitor gefitinib. Chinese herbal medicine (CHM) was effective in improving the quality of life and prolonging overall survival in patient with NSCLC. We aim to determine whether gefitinib plus CHM could prolong the progression-free survival (PFS) or median survival time (MST) in patients with NSCLC than gefitinib alone. We retrospectively analyzed 159 non-small-cell lung cancer patients with the method of retrospective case-control study, matching factors included gender, age categories (30-39,40-49,50-59,60-69,70-79), pathological stage (IIIB or IV), smoking status (never: <100 lifetime cigarettes, or ever: ≥100 lifetime cigarettes), pathology, and performance status. Among the 159 patients, 100 patients treated with gefitinib (250mg/day orally) plus CHM ("Fuzheng Kang'ai" decoction, a Chinese herbal medicine, 250ml/bid/day orally), 59 patients treated with gefitinib (250mg/day orally) only. PFS and MST were analyzed for the whole population. 58 pairs were matched successfully. 1 patient (treated with gefitinib) with the age of 27 years failed to be matched. Progression-free survival was significantly longer in patients treated with gefitinib plus CHM than with gefitinib: median PFS was 13.1 months (95% CI 6.50-19.70) with gefitinib plus CHM versus 11.43 months (95% CI 7.95-14.91) with gefitinib (log-rank P=0.013). Median overall survival was longer with gefitinib plus CHM than with gefitinib: median MST was 22.83 months (95% CI 17.51-28.16) with gefitinib plus CHM versus 18.7 months (95% CI 16.83-20.57) with gefitinib (log-rank P=0.049). The most common adverse event was rash, the incidence in the gefitinib plus CHM group was 41.38% while in the gefitinib group was 24.14% (P=0.048). This case-control analysis suggested that treatment with gefitinib plus CHM prolonged PFS and MST compared with gefitinib in patients with NSCLC, and it is worthy of further study.

10 April 2015 in Trials
Verified
Journal Article
Open access
PDF file
XYXiaobing Yang
Xiaobing Yang
WWWanyin Wu
Wanyin Wu
SLShunqin Long
Shunqin Long
HDHong Deng
Hong Deng
ZPZong-Qi Pan
Zong-Qi Pan
JCJiao-Zhi Cai
Jiao-Zhi Cai
Patients with advanced non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR) gene respond well to the EGFR tyrosine kinase inhibitor (TKI) gefitinib. Chinese herbal medicine (CHM) has been used as a complementary therapy for cancer for decades in China. CHM was proved to be effective in improving the quality of life (QOL) and reducing the toxicity associated with chemotherapy in patients with NSCLC. The purpose of the present trial is to determine whether CHM (Fuzheng Kang’ai decoction (FZKA), a CHM formula) combined with gefitinib results in longer progression-free survival with less toxicity than gefitinib alone. This is a randomized, placebo-controlled, double-blind trial. This trial is designed to determine if CHM (FZKA) combined with gefitinib results in longer progression-free survival with less toxicity than gefitinib alone. A total of 70 NSCLC patients with EGFR mutations will be randomly assigned to treatment group (gefitinib plus FZKA granules) or control group (gefitinib plus placebo). The primary endpoint is progression-free survival. Secondary endpoints are: (1) overall survival; (2) disease control rate; (3) QOL, measured with the questionnaire of Functional Assessment of Cancer Therapy-lung (FACT-L 4.0) and Lung Cancer Symptom Scale and (4) safety. In previous clinical practice, we found that CHM (FZKA) could improve the therapeutic efficacy of gefitinib. This study will provide objective evidence to evaluate the efficiency of CHM combined with gefitinib in NSCLC patients with EGFR mutations, and may provide a novel regimen for patients with NSCLC. Chinese Clinical Trial Registry ( www.chictr.org ): ChiCTR-IOR-14005679 , registered 17 December 2014.

25 February 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
ZGZiyan Gan
Ziyan Gan
JZJiahao Zhang
Jiahao Zhang
JHJinpeng Huang
Jinpeng Huang
SLShunqin Long
Shunqin Long
WWWanyin Wu
Wanyin Wu
YLYonglin Li
Yonglin Li
Objectives: To investigate the factors associated with in-hospital survival prognosis in participants with malignant tumors complicated by sepsis and to develop a predictive model. Methods: A retrospective study was conducted to collect data from 2,152 participants with malignant tumors complicated by sepsis, hospitalized at Guangdong Provincial Hospital of Chinese Medicine between January 2014 and June 2024. Univariate and multivariable logistic regression analyses were performed to identify independent risk factors, and the ADASYN oversampling technique was applied to address class imbalance. The dataset was randomly split into training and testing sets at an 8:2 ratio. Key features were selected using the recursive feature elimination (RFE) method, and eight machine learning models (logistic regression, decision tree, random forest, K-nearest neighbors, support vector machine, naive Bayes, stochastic gradient boosting, and neural network) were evaluated and hyperparameter-optimized. Results: A total of 2,152 participants were included in the study, with an in-hospital mortality rate of 12.6%. Multivariable analysis indicated that age, SOFA score, coagulation dysfunction, and metabolic abnormalities were important prognostic risk factors. The random forest model showed excellent discriminative ability on the validation set, with an AUC of 0.95, sensitivity of 91%, and specificity of 85%. A total of 10 features with the highest predictive value were selected using the RFE method, including troponin T, platelet distribution width, neutrophil count, red blood cell distribution width, fibrinogen, prothrombin time activity, aspartate transaminase, urea, low-density lipoprotein cholesterol, and creatinine. Conclusion: Age, SOFA score, coagulation dysfunction, and metabolic abnormalities are important prognostic risk factors for participants with malignant tumors complicated by sepsis. The random forest model constructed based on these key features has good predictive performance and can provide a powerful tool for the prognosis assessment of participants with malignant tumors complicated by sepsis. Future research needs to further validate the applicability and practical value of the model in different populations.

17 December 2025 in Phytomedicine
Verified
Journal Article
Closed access
QZQichun Zhou
Qichun Zhou
GZGangxing Zhu
Gangxing Zhu
YZYongchun Zou
Yongchun Zou
XYXiaoyan Yu
Xiaoyan Yu
MYMingnan Ye
Mingnan Ye
SWSumei Wang
Sumei Wang

1 June 2022
Verified
Journal Article
Closed access
JJJinhua Li Jinhua
Jinhua Li Jinhua
CCChunping Liu Chunping
Chunping Liu Chunping
YYYueyang Zhao Yueyang
Yueyang Zhao Yueyang
WWWanyin Wu Wanyin
Wanyin Wu Wanyin
PPPengtao Sun Pengtao
Pengtao Sun Pengtao
YYYushu Zhou Yushu
Yushu Zhou Yushu